Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Comment by LTOWNERon Feb 08, 2014 10:44am
150 Views
Post# 22187242

RE:RE:Be brave

RE:RE:Be braveI think by 'be brave' knoll really means be patient and mature.  But it does take nerves of steel to invest in speculative biotechs and by all means - keep informed!  Follow closely and question everything.

In the trial PharmaZ sited Wednesday, which I just got around to reading, they took a group of frail, barely active men and gave them higher doses of testosterone than are normally prescribed!  What were they thinking?  Not surprisingly the highest rate of CV-related events was in the group with the highest testosterone levels >1000ng.  I am thinking there are very few drugs on the market that would fare well when tested in a group of similar composition: This consisted of men with an average age of 74, who had substantial limitations in mobility and a high prevalence of hypertension, obesity, diabetes, hyperlipidemia and pre-existing heart  disease.  Further, a greater proportion of men in the testosterone group vs. the placebo group had a diagnosis of hyperlipidemia or were taking statins. 
 
“The testosterone doses in this trial may have been higher than those that are typically used in clinical practice and were higher than the doses used in some previous trials … the average testosterone concentrations during the intervention were in the middle of the normal range for young men.”
 
The researchers admit the sample was small and the number of adverse events was small. “The results of individual small trials may not be confirmed in large trials, and trials that have been stopped early tend to overestimate treatment differences …the lack of a consistent pattern in these events and the small number of overall events suggest the possibility that the differences detected between the two trial groups may have been due to chance alone … it is essential to recognize the role that chance may have played in the outcomes we observed.”

Independent clinical trials often would not stand up to the scrutiny of an FDA submission and can have an agenda - if only to get research funds and get published.

Bullboard Posts